Live Quote · AMEXCLDIHealthcare· Biotechnology

Calidi Biotherapeutics, Inc.

$0.15 5.70%($-0.01)
TickerSpark Score
58/100
Mixed
100
Valuation
20
Profitability
60
Growth
80
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLDI research report →

52-Week Range0% of range
Low
$0.12
Current
$0.15
High
$19.20
Company Overviewcalidibio.com

About the company

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.

CEO
Eric E. Poma
IPO
2021
Employees
28
HQ
San Diego, CA, US

Price Chart

-94.70% · this period
$11.98$6.06$0.15Jul 02Dec 31Jul 02
Valuation
Market Cap
$1.10M
P/E
-0.03
P/S
0.00
P/B
0.31
EV/EBITDA
0.19
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-438.03%
ROIC
-266.77%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-19,906,000 · 10.10%
EPS
$-5.95 · 83.33%
Op Income
$-20,240,000
FCF YoY
-8.64%
Performance & Tape
52W High
$19.20
52W Low
$0.12
50D MA
$0.19
200D MA
$0.85
Beta
1.30
Avg Volume
6.03M

Get TickerSpark's AI analysis on CLDI

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 17, 26Sanders Corazon (Corsee) D.other0
Dec 12, 25Camaisa Allansell850
Sep 3, 25Poma Eric Eother10,000
Sep 3, 25Fernandez Santidrian Antonioother35,000
Sep 3, 25Jackson Andrew C.other30,000
Aug 20, 25Lincoln Alternative Strategies LLCother0
Aug 21, 25Schoeneck James Abuy75,000
Aug 21, 25Schoeneck James Abuy75,000
Aug 21, 25Poma Eric Ebuy25,000
Aug 21, 25Poma Eric Ebuy25,000
Coverage · CLDI

Our CLDI coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CLDI yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CLDI report →
Internal Compare

Similar companies

Peers in the same neighborhood.